Pharmacogenomics
Oncology NGSFrom how a patient will respond to a medication to hereditary cancer risk and tumor profiling. Every result comes back as an interpreted, physician-ready report.
Turnkey pharmacogenomic testing programs, and oncology NGS panels in partnership with Celemics. Offer one, or both, with the same lab, logistics and reporting.
PharmacogenomicsA one-time cheek swab shows how a patient's genes may affect their response to medications, with a pharmacist-reviewed summary for the prescriber.
×Hybrid-capture panels for hereditary cancer risk, solid-tumor profiling and plasma ctDNA, each returned as an interpreted, physician-ready report.
A pharmacogenomic test reads the genes that control how your body activates and clears medications. Prescribers use the results to choose drugs and doses that are more likely to work and less likely to cause side effects.
Fictional data for illustration.
A short enrollment form. We send kits, requisitions and patient materials.
Kits shipped to youA painless cheek swab in the pharmacy, office or at the bedside.
No needlesCoverage is verified first, then our CLIA-certified lab genotypes the sample.
5–7 days after receiptA pharmacist-reviewed summary goes to the prescriber with clear recommendations.
Pharmacist-reviewedTurnkey PGx programs for hospitals, pharmacies, skilled nursing facilities and physician groups. Choose your setting to see how it runs.
Preemptive PGx designed to help reduce adverse drug reactions, alongside our oncology NGS portfolio.
Hospital programA pharmacist-led clinical service. We verify coverage and coordinate with prescribers.
Pharmacy programWe help identify residents whose medications have gene-based guidance, and handle collection on testing day.
SNF programLaunch PGx across your practices in two phases, with kits and materials provided.
Practice programNew to pharmacogenomics? Start with what PGx testing is
Most prescriptions start with a best guess. A one-time PGx test adds the patient's genetics to that decision.
Start with a common drug and see how the patient responds.
Adjust over weeks based on side effects and response.
Often found only after the patient experiences them.
Each new medication starts the guessing over.
Choose a drug with the patient's genetics already in mind.
Start from a dose informed by how the patient processes the drug.
Known gene-drug risks are flagged before prescribing.
One test result can inform the prescriptions that follow.
Medicare usually covers approved lab tests with no patient cost-share when its criteria are met. We verify each patient's coverage first. If a patient would owe anything, we contact them and get approval before testing.
×AchieveDx runs the lab and delivers every report.Celemics designs the oncology panels.
A CLIA-certified, high-complexity laboratory. We run our own PGx testing, and handle kits, logistics, sequencing, analysis and interpreted reports for the oncology panels.
Oncology panel design and hybrid-capture target enrichment, with more than 10 years designing NGS panels and ctDNA panels developed with Seoul National University Hospital.
Provides the right specimen and a completed requisition. No in-house bioinformatics needed.
Hereditary risk, somatic tumor profiling and plasma ctDNA analysis. Select a panel to see its specifications and full gene list.
Germline risk in a patient or family with a suspicious history.
Treatment-related variants in solid tumors, interpreted in the context of tumor type.
Tumor-specific ctDNA profiling for colorectal cancer.
Tumor-specific ctDNA profiling for breast cancer.
Tumor-specific ctDNA profiling for lung cancer.
Manufacturer reference specifications from Celemics product sheets (OncoRisk OR-PS-v1.3, CancerScreen CSS-PS-v1.3, Liquid Biopsy LB-PS-v1.4). ctDNA performance measured with Seraseq reference material. All panels are sequenced on the Element AVITI platform.18
Full portfolio detailsYour team provides the specimen and requisition. We handle sequencing, analysis and clinical interpretation.
Whole blood for OncoRisk, tumor tissue for CancerScreen 50, plasma for the ctDNA panels.
Kits, requisitions and logistics are provided by our team.
Celemics target enrichment and sequencing on Element AVITI, with variant analysis and QC.
Variant findings with evidence and clinical context, not a raw variant file.
| Context | FDA-approved therapy example |
|---|---|
| Metastatic NSCLC | Osimertinib, first-line metastatic setting |
Gene, coding and protein change, and variant class, with ClinVar, CIViC and classification evidence.
Actionable variants are matched to evidence levels, such as an AMP/ASCO/CAP Tier I therapy for EGFR L858R in metastatic NSCLC.
Relevant open clinical trials are listed by NCT ID, phase, biomarker and status, so the conversation can continue.
Every report closes with methodology, QC metrics, stated test limitations and a commitment to reclassify variants as new evidence is published. See sample reports
Review sample reports, choose your starting panels and plan a pilot with our team.
Three quick steps. A program specialist follows up with a recommended workflow, materials and a go-live timeline.
Your organization and the tests you pick will show here.
Anything you added while browsing is already selected.
We use your information only to respond to your inquiry. Please don't include patient health information.
An AchieveDx program specialist will reach out to schedule a short discovery call and walk through your plan.
A specialist reads your answers before reaching out.
We learn your workflow, patient population and goals.
Recommended workflow, kits and materials, and a go-live timeline.
A PGx test reads genes that control how your body activates and clears medications. Providers use the results to choose drugs and doses that are more likely to work and less likely to cause side effects.
With a simple cheek swab. No needles or blood draw. It can be done in a pharmacy, physician office, hospital unit or at a resident's bedside.
Typically 5–7 days after the lab receives the specimen. SNF programs receive results by encrypted email or fax within 5–10 business days.
Choose your starting panels, review sample reports with your oncology and pathology teams, confirm logistics, then run a pilot with a defined patient cohort. Contact us to begin.
OncoRisk uses whole blood. CancerScreen 50 uses fresh-frozen or FFPE tumor tissue. The ctDNA panels use plasma from a whole blood draw.
And 3–6% of U.S. hospital admissions are related to adverse drug reactions.
No needles. No blood draw. Done in the pharmacy, the office or at the bedside.
Coverage is verified first. Results 5–7 days after the lab receives the sample.
Your inherited genes don't change, so one result can inform many future prescriptions.
Coverage varies by plan. Any patient cost is confirmed first.
For hospitals, pharmacies, skilled nursing facilities and physician groups.